Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient.

about

Inhibiting TRK Proteins in Clinical Cancer Therapy.

P2860

Q54117764-9E995485-E0B8-4FF0-9AAA-BFA38923D52A

P2860

Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient.

Item

http://www.wikidata.org/entity/Q41548672

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Identification and characteriz ...... n a colorectal cancer patient.

@en

type

Item

label

Identification and characteriz ...... n a colorectal cancer patient.

@en

prefLabel

Identification and characteriz ...... n a colorectal cancer patient.

@en

P1476

Identification and characteriz ...... n a colorectal cancer patient.

@en

P2093

Adele Testi

http://www.w3.org/2001/XMLSchema#string

Alessio Pellegrinelli

http://www.w3.org/2001/XMLSchema#string

Antonella Isacchi

http://www.w3.org/2001/XMLSchema#string

Danielle Murphy

http://www.w3.org/2001/XMLSchema#string

Elena Ardini

http://www.w3.org/2001/XMLSchema#string

Emanuele Valtorta

http://www.w3.org/2001/XMLSchema#string

Filippo De Braud

http://www.w3.org/2001/XMLSchema#string

Filippo Pietrantonio

http://www.w3.org/2001/XMLSchema#string

Ge Wei

http://www.w3.org/2001/XMLSchema#string

Giovanni Fucà

http://www.w3.org/2001/XMLSchema#string

P2860

PACE-1, a novel protein that interacts with the C-terminal domain of ezrin

Current targeted therapies in the treatment of advanced colorectal cancer: a review

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.

NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer.

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.

MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.

NTRK gene fusions as novel targets of cancer therapy across multiple tumour types

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

NTRK1 fusion in glioblastoma multiforme

P304

55353-55360

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.19512

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28903424

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

5589663

http://www.w3.org/2001/XMLSchema#string

Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient.

about

P2860

P2860

Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932